Condition: Recurrent Respiratory Papillomatosis · Papillomavirus Infection · Papillomaviridae · Sponsor: Precigen, Inc
This open-label study evaluates safety, vector shedding, and retreatment efficacy of Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP). Two cohorts will be enrolled (n=30): Cohort 1 to assess the magnitude and duration of adenoviral vector shedding in urine, feces, skin, and nasal tissue; Cohort 2 to assess the complete response rate following retreatment.
This description comes directly from the study's public registry record.
Head of Clinical Operations · 301-556-9900 · clinicaltrials@precigen.com
Always discuss trial participation with your own doctor first.
| Winship Cancer Institute, Emory University | Atlanta, Georgia, United States | Recruiting |
| National Institute of Health | Bethesda, Maryland, United States | Recruiting |
| University of Cincinnati | Cincinnati, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06538480